Asset
Zorevunersen
Stoke Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06872125 | phase3 | recruiting | 2025-06-04 | 2027-03-01 | Stoke Therapeutics, Inc | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
| NCT04740476 | phase2 | active_not_recruiting | 2021-01-20 | 2029-03-31 | Stoke Therapeutics, Inc | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome |
FDA applications (0)
This company has no applications containing this asset.